Search the Newsreel

TriCo Bancshares (TCBK) Slips 0.69% as Shares Settle Mid-Range Between Support and Resistance - Negative Gamma

Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Hold Rating

Maxim Group has reiterated its Hold rating on Capricor Therapeutics (CAPR.US). The article does not provide specific details on the reasons for this rating or any financial metrics.

Wall Street Zen Downgrades Capricor Therapeutics (NASDAQ:CAPR) to Strong Sell

Wall Street Zen has downgraded Capricor Therapeutics (NASDAQ:CAPR) to a "strong sell" rating following a series of negative developments. The FDA's advisory committee voted against the effectiveness of Capricor's lead candidate, Deramiocel, and the company is facing securities-fraud investigations and shareholder lawsuits. Consequently, other …

Shareholder Alert - Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action Lawsuit

Robbins LLP has filed a securities class action lawsuit against Capricor Therapeutics, Inc. on behalf of investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor misled investors regarding the FDA approval prospects for its lead product …

CAPR INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

A class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) alleging that the company made materially false or misleading statements regarding changes to the statistical analysis plan for Deramiocel and the FDA's lack of agreement to these changes, creating a significant …

Crédit Agricole S.A. gibt Ergebnisprognose für 2028 ab

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Americold Realty Trust, Inc. (COLD) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into Americold Realty Trust, Inc. (COLD) following the company's disclosure of a significant impairment charge. This charge, estimated between $305 million and $320 million, resulted from the termination and wind-down of operations at two of …

TCBK|Trico Bancshares|Price:57.900|Chg%:-0.010

This article provides a comprehensive stock analysis of Trico Bancshares (TCBK), highlighting its strong fundamentals, high growth potential, and relatively fair valuation. It notes high institutional ownership and recent "Hold" ratings from analysts, with expectations for an upward trend in the medium term. The …

SummitTX Capital L.P. Takes Position in Americold Realty Trust Inc. $COLD

SummitTX Capital L.P. has initiated a new position in Americold Realty Trust Inc. (NYSE:COLD) by purchasing 92,950 shares valued at approximately $1.07 million. Institutional investors now own 98.14% of the company, and analyst sentiment is mixed with a consensus "Hold" rating. Americold Realty Trust …

Capricor Therapeutics: FDA Advisory Panel Votes 9-3 That Evidence Does Not Support Deramiocel for DMD Cardiomyopathy

An FDA advisory committee voted 9-3 that the available evidence does not support the effectiveness of Deramiocel for Duchenne Muscular Dystrophy (DMD) cardiomyopathy. While this recommendation is non-binding, the FDA will consider it as part of the Biologics License Application (BLA) review, with the …

Crédit Agricole S.A. legt Ergebnisse für das zweite Quartal und das erste Halbjahr bis zum 30. Juni 2026 vor

Crédit Agricole S.A. communique ses objectifs de résultats pour 2028

Price Action: LIC Housing Finance, Data Patterns down 3% post earnings; Pricol gains 4%

Stock Alert: RailTel Corp, Pricol, Filatex India, Mazagon Dock, LIC Housing Finance

Capricorn Energy Confirms Share Capital and Voting Rights Update

CREDIT AGRICOLE SA: STRONG ACTIVITY, ACCELERATING THE AI TRANSFORMATION

CREDIT AGRICOLE SA STRONG ACTIVITY, ACCELERATING THE AI TRANSFORMATION CRÉDIT AGRICOLE S.A. CRÉDIT AGRICOLE GROUP In m€ Q2 2026 Var. Q2/Q2 Q2 2026 Var.Q2/Q2 Revenues 7,363 +7.7% 10,880 +12.9% Expenses -3,870 +4.6% -6,143 +4.6% Gross Operating Income 3,493 +11.4% 4,737 +25.8% Cost of risk …

Pricol shares surge over 3% after Q1 profit jumps 34% YoY to Rs 67 crore, revenue climbs 23.5%

Levi & Korsinsky Announces Investigation of Securities Claims Against Capricor Therapeutics, Inc. (CAPR)

Levi & Korsinsky has launched an investigation into Capricor Therapeutics, Inc. (CAPR) following a significant stock drop. The drop occurred after FDA briefing documents raised concerns about the cardiac efficacy of Deramiocel and revealed a change in the statistical analysis plan. The firm is …

Americold faces $305M-$320M impairment charge, stock drops 7.8% amid fraud investigation.

Americold Realty Trust announced a non-cash impairment charge ranging from $305 million to $320 million due to the discontinuation of operations at its automated retail centers, following the termination of a deal with ADUSA Distribution. This news caused Americold's stock to fall by 7.84%. …

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

Capricor Therapeutics announced that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for Duchenne muscular dystrophy cardiomyopathy, with 9 votes against and 3 for. Despite the non-binding negative vote on a narrow …

Capricorn Energy PLC Revenue Breakdown – LSE:CNE

CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC

ATLANTA, July 30, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 27, 2026, STATNews reported that: “The Food and Drug Administration said Monday that Capricor …

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash

Hagens Berman has opened an investigation into Capricor Therapeutics (NASDAQ: CAPR) following a significant stock crash after the FDA questioned the company's claims regarding its Duchenne muscular dystrophy drug. The FDA's briefing document revealed discrepancies between Capricor's characterization of its Phase 3 HOPE-3 trial …

Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) (“Capricor” or the “Company”) for potential violations of the federal securities laws. On July 27, …

Capricor stock downgraded at Oppenheimer (CAPR:NASDAQ)

Oppenheimer downgraded Capricor Therapeutics (CAPR) after an FDA advisory committee voted against endorsing its lead drug, Deramiocel. This news caused Capricor's stock to drop over 45%, reaching a new 52-week low.

Marico profit plunges after four years

Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy

Capricor Therapeutics' stock fell sharply after an FDA advisory panel overwhelmingly rejected the sufficiency of evidence supporting its Duchenne muscular dystrophy cell therapy, Deramiocel. The panel's decision echoed FDA staff concerns regarding post hoc changes to key analyses after the late-stage trial. This rejection …

Duchenne Therapy Has Aug. 22 FDA Action Target After Panel Vote

Capricor Therapeutics announced that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 against the effectiveness of Deramiocel for cardiomyopathy in Duchenne muscular dystrophy (DMD). This non-binding vote focused on a narrower indication than proposed, with the company noting supportive discussion on …

FDA Panel Says "No" To Capricor's DMD Drug Deramiocel, Citing "Fragile" Data; Shares Plunge

(RTTNews) - Shares of Capricor Therapeutics, Inc. (CAPR) have been hit hard this week following adverse regulatory developments related to Deramiocel, the company's investigational cell therapy for Duchenne muscular dystrophy-associated cardiomyopathy. Duchenne muscular dystrophy (DMD) is a devastating genetic disorder characterized by progressive weakness …

Trico Bancshares (TCBK) Institutional Confidence

This article analyzes the institutional confidence score for Trico Bancshares (TCBK), which currently stands at 7.00, placing it 70th in the Banking Services industry. Institutional shareholding has increased to 78.15%, with James Simons being a major individual holder. The article also lists the top …

Americold Realty Trust (COLD) Projected to Release Quarterly Earnings on Thursday

Americold Realty Trust (COLD) is slated to release its Q2 2026 earnings before market open on Thursday, August 6th. Analysts project a slight loss of $0.0006 per share on revenues of $613.5 million, with full-year EPS guidance set between $1.20 and $1.30. The company …

Public Employees Retirement System of Ohio Decreases Stake in Americold Realty Trust Inc. $COLD

The Public Employees Retirement System of Ohio reduced its holding in Americold Realty Trust Inc. by 14.4% in Q1, selling 69,250 shares and retaining 411,724 shares worth $4.7 million. Despite mixed analyst ratings, with a consensus "Hold" and a $15.25 price target, Americold exceeded …

Capricor Duchenne cell therapy voted down by FDA panel

An FDA advisory panel voted against Capricor Therapeutics' experimental cell therapy, deramiocel, for Duchenne muscular dystrophy-related cardiomyopathy, citing insufficient evidence of effectiveness. This decision follows a contentious regulatory process and skepticism from FDA scientists regarding Capricor's data analysis. The FDA is expected to make …

Pricol Q1 profit jumps 34% as revenue crosses ₹1,100 crore

TriCo Bancshares Q2 2026 Earnings: EPS Slightly Beats Estimates, Stock Edges Lower - Net Income Trends

TriCo Bancshares Q2 2026 Earnings: EPS Slightly Beats Estimates, Stock Edges Lower - Dividend Earnings Report